Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies
EMERYVILLE, Calif., January 22, 2018 — Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing